IntegraGen's mission is to translate molecular research to clinical practice through the identification of novel genetic biomarkers and the subsequent commercialization of molecular diagnostic tests based on these discoveries. The company also strives to be a leader in providing cutting edge genomic services to academic researchers and life sciences companies based on the Company's technological expertise and scientific know how.
TypePublic
HQÉvry, FR
Founded2000
Size (employees)31 (est)+15%
Websiteintegragen.com
IntegraGen was founded in 2000 and is headquartered in Évry, FR
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at IntegraGen

Bernard Courtieu

Bernard Courtieu

Chairman and Chief Executive Officer
Laurence Riot Lamotte

Laurence Riot Lamotte

CFO
Francois Liebaert

Francois Liebaert

Vice President of R&D and Medical Affairs
Francis Rosseau

Francis Rosseau

Director of Genomics
Emmanuel Martin

Emmanuel Martin

Sales and Marketing Director, Services and Arrays
Show more

IntegraGen Office Locations

IntegraGen has offices in Cambridge and Évry
Évry, FR (HQ)
Genopole Campus 1 – Bât. 8 5, Rue de Henri Desbruères
Cambridge, US
485 Massachusetts Ave
Show all (2)
Report incorrect company information

IntegraGen Online and Social Media Presence

Embed Graph
Report incorrect company information

IntegraGen Blogs

IntegraGen presents new data expanding application of miR-31 to stage III colon cancer during ESMO 2018

Analysis of PETACC-8 clinical trial samples demonstrates company’s proprietary miR-31 microRNA biomarkers identifies subpopulations of patients with resected stage III colon cancer who benefit from the addition of cetuximab to FOLFOX adjuvant therapy IntegraGen announced today that it presented dat…

IntegraGen Reports Financial Results for 1st Half of 2018

IntegraGen has announced today its financial results for the first half of semester 2018 with the accounts having been examined by the company’s Board of Directors on September 20, 2018. Sales revenue: 3.7 M€, +17% vs. H1 2017 Significant growth in genomics services Operating profit: -0.5 M€, + 57%…

IntegraGen nominated for a 2018 PrixGalien MedStartup Award

IntegraGen has been nominated for a 2018 PrixGalien MedStartup Award, a joint initiative between The Galien Foundation and Business France to encourage and reward international partnerships between French and North American innovators in the Life Sciences Industry. IntegraGen was selected as a nomin…

IntegraGen’s licensing partner GoPath Labs announces new CPT Code for reimbursement of miR-31-3p test in the U.S.

GoPath Laboratories, IntegraGen’s North American licensing partner for the company’s miR-31-3p test, announced that the American Medical Association (AMA) has assigned a new, discreet CPT (Current Procedural Technology) code to facilitate reimbursement of miR-31now®, a proprietary miRNA-based molecu…

IntegraGen Announces Publication of miR-31-3p Data in Clinical Cancer Research

IntegraGen announces the publication of the results of a definitive study reporting on the analysis of the expression of miR-31-3p in tumors from 370 RAS wild-type (WT) metastatic colorectal cancer (mCRC) patients enrolled in the FIRE-3 clinical trial (AIO KRK-0306). The paper, entitled “Validation …

The SeqOIA Cooperative Health Group selects IntegraGen as the operator of its sequencing platform as part of the France Genomic Medicine 2025 Plan

IntegraGen has announced that it has been selected by the Sequencing Omics Information Analysis (SeqOIA) Cooperative Health Group (GCS) for the operation of its high throughput sequencing platform. The SeqOIA GCS, which includes the Assistance Publique- Hôpitaux de Paris, the Institut Curie and the …
Show more

IntegraGen Company Life and Culture

Report incorrect company information